about
Hepatitis B: the virus and diseaseAcute liver failure including acetaminophen overdoseRole of inflammation and infection in the pathogenesis of human acute liver failure: Clinical implications for monitoring and therapyOpioid Drugs in Patients With Liver Disease: A Systematic ReviewHepatitis G virus: is it a hepatitis virus?Hepatitis G virus infection in fulminant hepatic failureInhibition of glycogen synthase kinase 3β ameliorates D-GalN/LPS-induced liver injury by reducing endoplasmic reticulum stress-triggered apoptosisOutcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study.Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure.18Beta-glycyrrhetinic acid ameliorates acute Propionibacterium acnes-induced liver injury through inhibition of macrophage inflammatory protein-1alpha.Oxidative stress promotes D-GalN/LPS-induced acute hepatotoxicity by increasing glycogen synthase kinase 3β activity.Update in liver transplantation.Brain edema in acute liver failure: inhibition by L-histidine.Diosmetin exerts anti-oxidative, anti-inflammatory and anti-apoptotic effects to protect against endotoxin-induced acute hepatic failure in mice.Acute hepatic failure: a Western perspective.Molecular adsorbent recirculating system: albumin dialysis-based extracorporeal liver assist device.Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period.Quantification of viral DNA and liver enzymes in plasma improves early diagnosis and management of herpes simplex virus hepatitisAcute liver failure and liver transplantationAcute liver failure as a rare initial manifestation of peripheral T-cell lymphoma.Population-based surveillance for acute liver failure.Random forest classification of etiologies for an orphan disease.Viral hepatitis: past and future of HBV and HDV.Acute liver failure in children: A regional experience.Peroxisome proliferator-activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway.Predictive value of arterial ammonia for complications and outcome in acute liver failure.Anti-inflammatory effect of recombinant thrombomodulin for fulminant hepatic failure.A retrospective autopsy study of histopathologic spectrum and etiologic trend of fulminant hepatic failure from north IndiaAcute liver failure in adults: an evidence-based management protocol for cliniciansAcute liver failure: Summary of a workshopReview article: non-biological liver support in liver failure.Experimental study of bioartificial liver with cultured human liver cells.Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomesUse of Magnetocapsules for In Vivo Visualization and Enhanced Survival of Xenogeneic HepG2 Cell TransplantsBrain edema in acute liver failure: role of neurosteroids.Brain aquaporin-4 in experimental acute liver failure.Liver transplant center variability in accepting organ offers and its impact on patient survival.Inhibition of glycogen synthase kinase 3β promotes autophagy to protect mice from acute liver failure mediated by peroxisome proliferator-activated receptor α.Racial and ethnic differences in presentation, etiology, and outcomes of acute liver failure in the United States.Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure.
P2860
Q24642704-BED96DAD-BE72-4BF6-BAAB-56B41642E729Q24647134-FDFFBAE7-F746-4070-939F-31478DAE47B3Q26741218-491316F8-EFA8-4CCF-80CF-D278DC5E66DDQ26743429-AF4852AF-DEDF-4554-AEB8-86A842DB2731Q27472732-7C90BC26-60B0-4414-84E2-BF20F7416871Q27480284-F32A907F-2E29-4F1A-975A-EB364D0F3A78Q28484135-32E03B68-D5F0-4E92-8577-04835C641F46Q30417774-7122CC20-F47D-4BA6-87EC-3E6FDBC3819EQ33269555-43F3C8FF-06FF-4805-84AE-18694480E6B9Q33569635-D16EFB04-55F1-4AEF-841C-FD4B73F06331Q33600191-D9FD53B3-D5F4-446F-B9B9-5A5FA3984B74Q33647283-65B4B6D6-9FC2-4160-B0B4-1D665CCE6B31Q33703761-2428FE59-9635-440A-A834-C7B0043E9F4FQ33761519-34F33959-58D0-438C-9058-6C081D86C26BQ33939738-3FD677C2-8AFE-44A1-8BED-5B7BB86DAEA2Q34163425-86DD45EC-A193-4E90-B12A-696BC3D53955Q34194045-44D5BE4B-13AE-44B8-AEF1-5B173941E888Q34354018-6725BDA3-0DE8-4FD7-8EA5-D86FB32ECB85Q34377780-9958A34E-C1F9-49A3-A8BB-0C01BB3C7C3FQ34391540-511049BD-3E2D-4477-A34C-6826658DE240Q34645492-293C7DB5-FDEE-4E6B-8CFF-01E77F514688Q35027782-2464BCC1-B32C-4FE4-AA3E-85A051885D61Q35045045-4B0A8B44-F5F9-4E84-97D2-85E02B91DCF9Q35072313-60E90C87-EEFF-4E5D-B402-1348E59B18B1Q35679584-78ED0722-38B6-4CF0-B760-8F6EDD49E0E0Q35760800-BE09DC3D-3957-443A-9EA9-0C2D6831724DQ35843130-76510489-4DFB-40EB-839B-266B5869BA34Q35981200-FAA220DA-0E31-477B-A9AE-C808F392FCE9Q36002196-0C4CF3B3-4932-438D-B32F-379925C5029EQ36054934-CBCD1F0F-E27A-45C6-99C7-9C281BBAB28CQ36372530-EC998400-4406-452B-A02D-9B546213EC05Q36396905-3BA9F28F-64C9-41D2-A429-71FB46585741Q36421177-DEC6328F-6868-4D96-8CD6-659DE145E938Q36501873-D58A5B64-E9E4-46F4-A805-85F8DC7E165AQ36532468-8401503C-ABE1-40C0-BA84-69E504486BA4Q36533457-185717F6-8496-4D87-A20C-DFCF687C53F1Q36706307-F40EBA31-68BA-4DFF-891E-573A5994D8D1Q36775015-7507C5F8-EAFA-47CA-90E0-7DA0771D8C5CQ36812921-F5D1292A-5214-477D-A1B8-C17CE8FFAF1BQ36874626-F6266129-81F7-4F5D-853F-EFF0AE856D43
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Fulminant hepatic failure: summary of a workshop.
@en
type
label
Fulminant hepatic failure: summary of a workshop.
@en
prefLabel
Fulminant hepatic failure: summary of a workshop.
@en
P2093
P1433
P1476
Fulminant hepatic failure: summary of a workshop.
@en
P2093
Carithers RL Jr
Hoofnagle JH
P304
P356
10.1016/0270-9139(95)90434-4
P407
P577
1995-01-01T00:00:00Z